Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Multiple Myeloma 3Sarcoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma 1Liver Neoplasms 1Leukemia, Plasma Cell 1Desmoid Tumors 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 9Paclitaxel 9Doxorubicin 6Cyclophosphamide 6Carboplatin 5130-nm albumin-bound paclitaxel 5durvalumab 3yeast-CEA vaccine 2talazoparib 2sacituzumab govitecan 2olaparib 2glembatumumab vedotin 2avelumab 2Taxes 2Radiotherapy 2Leucovorin 2Fluorouracil 2Cisplatin 2Capecitabine 2Biopsy 2Albumin-Bound Paclitaxel 2ALT-803 2zimberelimab 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab duocarmazine 1tislelizumab 1taxane 1sabizabulin 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Triple Negative Breast Neoplasms × liposomal doxorubicin × Clear all
NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡